Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of the FIL on Elderly Frail Patients With DLBCL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically proven CD20 positive Diffuse Large B-cell Lymphoma according to WHO classification (local pathologist)~2. Age ≥ 70 years~3. Previously untreated~4. CGA assessment performed before starting treatment~5. FRAIL patients defined as follows~   Age \> 80 years (with UNFIT profile):~   ADL ≥ 5 residual functions and/or IADL ≥ 6 residual functions and/or CIRS: 0 comorbidity of grade 3-4 and 5-8 comorbidities of grade 2~   Age \< 80 (ONLY one of the following criteria):~   ADL ≤ 4 residual functions IADL ≤ 5 residual functions CIRS: 1 comorbidity of grade 3-4 or \> 8 comorbidities of grade 2~6. Ann Arbor Stage I - IV (Appendix F)~7. At least one bi-dimensionally measurable lesion defined as \> 1.5 cm in its largest dimension on CT scan~8. ECOG performance status of 0- 3 (Appendix E)~9. No active hepatitis C virus (HCV) infection. In case of HCV positivity HCV-RNA is required. Only patients with HCV-RNA negative are accepted.~10. Adequate hematologic function (unless caused by bone marrow infiltrate), defined as follows:~    * Hemoglobin \> 10 g/dL~   * WBC \> 2500/mmc with PMN \> 1000/ mmc~   * Platelets count ≥ 75000/mmc~   * Creatinine clearance ≥ 10 mL/min~11. Ability and willingness to comply with the study protocol procedure~12. Life expectancy \> 6 months~13. Patients must give written informed consent.~14. Male subjects must practice complete abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 28 days following investigational product discontinuation, even if he has undergone a successful vasectomy.~Exclusion Criteria:~1. Histological diagnosis different from CD20 positive Diffuse Large B-cell Lymphoma are excluded.~2. Previous exposure to cytotoxic agents~3. Suspect or clinical evidence of CNS involvement by lymphoma~4. Contraindication to the use of Rituximab or of Lenalidomide~5. HBsAg positivity; HBsAg-negative patients with anti-HBc antibody can be enrolled if Hepatitis B Virus (HBV)-DNA are negative and antiviral treatment with Lamivudine or Tenofir is provided.~6. HIV positivity~7. Active herpes zoster infection; previously infected patients is accepted only with concomitant treatment with Valacyclovir.~8. Any history of other malignancies within 5 years prior to study entry except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer~9. AST /ALT \> 2 x UNL; bilirubin \> 2 x UNL; serum creatinine \> 2.5 mg /dL~10. Creatinine clearance \< 10 mL/min~11. Evidence of any severe active acute or chronic infection~12. Severe cardiac dysfunction (NYHA grade III-IV)~13. Any other co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent~14. Absence of caregivers in non-autonomous patients

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 arm for all patient: Ritux-Dexame-Lena (Type: EXPERIMENTAL): Rituximab-Dexamethasone-Lenalidomide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete